Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
21 November 2025GSK and Fleming Initiative scientists unite to target AMR with advanced AI
GlaxoSmithKline (GSK) will invest £45 million in a major new partnership with the Fleming Initiative at Imperial College London to accelerate the fight against antimicrobial resistance (AMR) using advanced artificial intelligence. Beginning in early 2026, both partners will launch six AI-powered “Grand Challenges” that span the full AMR spectrum: discovering new antibiotics and antifungals, predicting […]
Read more... -
19 November 2025A new gateway to global antimicrobial resistance data
EMBL-EBI has launched a new global AMR data portal that integrates bacterial genome sequences, antimicrobial susceptibility data (including MICs), resistance gene annotations, and detailed sample metadata into one accessible resource. Built on EMBL-EBI’s existing infrastructure (ENA, BioSamples, UniProt, InterPro, MGnify, Ensembl), the portal’s first release incorporates high-quality genotype–phenotype datasets from Imperial College London’s CABBAGE project, […]
Read more... -
17 November 2025Antibacterial products in clinical development for bacterial priority pathogens
The latest WHO review (Feb 2025) identifies 90 antibacterial products in clinical development worldwide—50 antibiotics and 40 non-traditional agents—but highlights that only a small fraction target the WHO priority pathogens with truly novel mechanisms. Of these, 27 antibiotics address priority pathogens, 21 show some activity against the most critical Gram-negative threats, and only 11 meet […]
Read more...
More news related to Smart innovation
